Loading...
OTCM
CLPBY
Market cap19bUSD
Oct 10, Last price  
8.85USD
1D
0.23%
1Q
-5.55%
Jan 2017
31.50%
Name

Coloplast A/S

Chart & Performance

D1W1MN
P/E
2.54
P/S
0.47
EPS
22.41
Div Yield, %
0.12%
Shrs. gr., 5y
1.08%
Rev. gr., 5y
8.54%
Revenues
27.03b
+10.33%
6,232,000,0006,709,000,0008,042,000,0008,463,000,0008,820,000,0009,537,000,00010,172,000,00011,023,000,00011,635,000,00012,428,000,00013,909,000,00014,681,000,00015,528,000,00016,449,000,00017,939,000,00018,544,000,00019,426,000,00022,579,000,00024,500,000,00027,030,000,000
Net income
5.05b
+5.62%
553,000,000466,000,000370,000,000715,000,000883,000,0001,243,000,0001,819,000,0002,194,000,0002,711,000,0002,390,000,000899,000,0003,143,000,0003,797,000,0003,845,000,0003,873,000,0004,197,000,0004,825,000,0004,706,000,0004,783,000,0005,052,000,000
CFO
2.77b
-34.55%
1,353,000,000966,000,0001,004,000,0001,324,000,0001,830,000,0001,769,000,0002,205,000,0002,649,000,0003,136,000,0003,149,000,0003,337,000,0003,028,000,0003,251,000,0004,361,000,0004,357,000,0004,759,000,0005,290,000,0005,099,000,0004,226,000,0002,766,000,000
Dividend
May 17, 20240.01047024 USD/sh
Earnings
Nov 04, 2025

Profile

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
IPO date
Jan 01, 1983
Employees
14,700
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
27,030,000
10.33%
24,500,000
8.51%
Cost of revenue
19,696,000
17,677,000
Unusual Expense (Income)
NOPBT
7,334,000
6,823,000
NOPBT Margin
27.13%
27.85%
Operating Taxes
1,343,000
1,242,000
Tax Rate
18.31%
18.20%
NOPAT
5,991,000
5,581,000
Net income
5,052,000
5.62%
4,783,000
1.64%
Dividends
(4,720,000)
(4,247,000)
Dividend yield
2.40%
2.64%
Proceeds from repurchase of equity
500,000
9,134,000
BB yield
-0.25%
-5.67%
Debt
Debt current
5,338,000
7,345,000
Long-term debt
18,278,000
13,116,000
Deferred revenue
199,000
Other long-term liabilities
155,000
6,000
Net debt
22,726,000
19,446,000
Cash flow
Cash from operating activities
2,766,000
4,226,000
CAPEX
(1,166,000)
(1,241,000)
Cash from investing activities
(1,336,000)
(8,957,000)
Cash from financing activities
(1,518,000)
5,265,000
FCF
(2,728,000)
14,539,000
Balance
Cash
788,000
911,000
Long term investments
102,000
104,000
Excess cash
Stockholders' equity
14,111,000
14,860,000
Invested Capital
40,726,000
29,400,000
ROIC
17.09%
20.13%
ROCE
16.97%
21.65%
EV
Common stock shares outstanding
224,900
215,500
Price
875.00
17.04%
747.60
-3.63%
Market cap
196,787,500
22.15%
161,107,800
-2.41%
EV
219,513,500
181,709,800
EBITDA
8,624,000
7,892,000
EV/EBITDA
25.45
23.02
Interest
882,000
638,000
Interest/NOPBT
12.03%
9.35%